LeMaitre Vascular, Inc. (LMAT)

Check out top investors' recommendation for LMAT
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
LeMaitre Vascular, Inc., together with its subsidiaries, engages in the development, manufacture, and marketing of medical devices and implants for the treatment of peripheral vascular disease worldwide. Its products include embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters; perfusion catheters that temporarily perfuse blood and other liquids into the vasculature; carotid shunts to temporarily divert blood to the brain during the removal of plaque from the carotid artery; and laparoscopic cholecystectomy devices to inject dye into the cystic duct during laparoscopic cholecystectomy. The company also offers manual contrast injectors for the injection of contrast media into blood vessels; modeling catheters to apply radial pressure to the inside of an aortic stent graft for sealing; radiopaque tape to improve the precision of vascular and endovascular procedures; and remote endarterectomy devices to remove severe atherosclerotic blockages from the arteries of the leg. In addition, it provides valvulotomes for use as a bypass vessel to carry blood past diseased arteries to the lower leg or the foot; vascular grafts to bypass or replace diseased arteries; vascular patches that are synthetic and biological patches for use in closing incisions in a blood vessel; vein strippers for single-incision removal of varicose veins; and vessel closure systems to attach blood vessels for dialysis access. LeMaitre Vascular, Inc. markets its products through direct and indirect sales force, and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Scott Henry Roth Capital Partners LLC Buy   Jun 08, '18     38.00  Jun 08, '19  N/A 
Rick Wise Stifel Nicolaus & Company, Inc. Buy   Oct 27, '17     35.00  Oct 27, '18  N/A 
Rick Wise Stifel Nicolaus & Company, Inc. Buy   Jul 28, '17     32.00  Jul 28, '18  N/A 
Jason Mills Canaccord Genuity Buy   Feb 27, '17     27.00  Feb 27, '18  N/A 
Jason Mills Canaccord Genuity Buy   Jan 23, '17     25.00  Jan 23, '18  N/A 
Jason Mills Canaccord Genuity Buy   Sep 06, '16     21.00  Sep 06, '17  N/A 
Michael Petusky Noble Financial Capital Mkts Buy   Feb 25, '16   14.95  15.50  Feb 25, '17  48.29% 
Jason Mills Canaccord Genuity Buy   Feb 24, '16   13.18  16.00  Feb 24, '17  66.16% 
Jason Wittes Brean Murray, Carret & Co. Buy   Dec 04, '15   15.61  17.50  Dec 04, '16  43.63% 
Jason Mills Canaccord Genuity Buy   Dec 04, '15   15.61  18.50  Dec 04, '16  43.63% 
Jason Mills Canaccord Genuity Buy   Oct 28, '15   13.83  16.50  Oct 28, '16  52.64% 
Jason Mills Canaccord Genuity Buy   Apr 29, '15   8.56  13.00  Apr 29, '16  94.74% 
Jason Mills Canaccord Genuity Buy   Oct 30, '13   7.42  11.50  Oct 30, '14  -2.29% 
Jason Mills Canaccord Genuity Buy   Feb 26, '13   6.00  9.50  Feb 26, '14  34.00%